Safety and Immunogenicity of a Human Epidermal Growth Factor Receptor 1 (HER1)-Based Vaccine in Prostate Castration-Resistant Carcinoma Patients: A Dose-Escalation Phase I Study Trial

• Asıl Yazarlar: Iraida Caballero (Yazar), Lazaro E. Aira (Yazar), Anabel Lavastida (Yazar), Xitlally Popa (Yazar), Javier Rivero (Yazar), Joaquín González (Yazar), Mónica Mesa (Yazar), Narjara González (Yazar), Kelly Coba (Yazar), Patricia Lorenzo-Luaces (Yazar), Barbara Wilkinson (Yazar), Yuliannis Santiesteban (Yazar), Yanela Santiesteban (Yazar), Mayelin Troche (Yazar), Eduardo Suarez (Yazar), Tania Crombet (Yazar), Belinda Sánchez (Yazar), Angel Casacó (Yazar), Amparo Macías (Yazar), Zaima Mazorra (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Frontiers Media S.A., 2017-05-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Metastatic castration-resistant prostate cancer (CRPC) remains incurable due to the lack of effective therapies. Activation of the human epidermal growth factor receptor 1 (HER1) in prostate cancer contributes to metastatic progression as well as to disease relapse. Here, we determined the toxicity...